Terlipressin Hrs denied for failing step therapy by Humana?

Humana's specific coverage criteria for terlipressin hrs are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Step Therapy for Terlipressin — and How to Override It

Terlipressin is FDA-approved for hepatorenal syndrome type 1 (HRS-1), a life-threatening renal complication of advanced cirrhosis. Despite this approval, Humana's coverage policy may require documentation that other vasoconstrictor or supportive therapies were tried and found inadequate before terlipressin will be authorized. This is a step-therapy ("fail first") requirement.

### Why This Denial Happens

Humana's step-therapy protocol for HRS treatments is designed to ensure that lower-cost or more established alternatives are considered first. The policy may require prior use of other agents that have been used off-label or as standard of care in this setting. When the prior-authorization request does not include documentation of these prior steps — or the patient's clinical situation made those steps inappropriate — the system generates an automatic denial.

### Why It's Appealable — Including Step-Therapy Override

Step-therapy requirements are subject to clinical override. Many states have enacted step-therapy override laws requiring the insurer to grant an exception when required prior steps are contraindicated, clinically inappropriate, or were already tried and failed. Even where no state law applies, ACA §2719 external-review and ERISA §503 full-and-fair review rights allow an independent physician to assess whether the step-therapy protocol is clinically reasonable for this patient. File for external review within approximately four months of the denial notice; expedited review is available when the patient's condition is urgent.

### Concrete Appeal Process

1. Identify the required steps — Request Humana's written step-therapy policy for HRS/terlipressin and identify precisely which prior treatments must be documented. 2. Step-therapy override or exception — Submit a clinical exception request explaining why the required steps are clinically inadequate, contraindicated, or were already attempted and failed. 3. Internal appeal — File within the deadline on the denial letter with the full documentation package. 4. Expedited review — For hospitalized patients with active HRS-1, the prescriber should certify urgency. 5. External review — Request independent review after an adverse internal decision; an independent reviewer applying clinical standards — not just Humana's protocol — is the strongest venue for step-therapy overrides in life-threatening conditions.

### Documentation to Gather

• Diagnosis confirmation — hepatologist or intensivist chart notes documenting HRS-1, consistent with the criteria in the FDA-approved prescribing information and current professional society guidance.
• Prior-treatment history — for each agent Humana requires as a prior step: dates, clinical setting, outcomes, and documented reason for discontinuation, inadequate response, or why the step was clinically inappropriate for this patient.
• Clinical severity — chart documentation of the urgency and acuity of the patient's current condition, including organ-function trajectory.
• Prescriber medical-necessity letter — the treating hepatologist or intensivist should address each step-therapy requirement directly, explain why terlipressin is now the appropriate next step, and cite the applicable AASLD or other relevant professional society guideline.

### Criteria-Mapping Structure

Obtain Humana's step-therapy policy and list every required prior step in a table. For each step, insert the chart documentation that shows it was attempted and failed, or the prescriber's documented clinical reason it was inappropriate. If terlipressin is required urgently without the ability to complete prior steps, this section of your appeal should foreground that clinical reality. A structured, criterion-by-criterion rebuttal — not a narrative letter alone — is the format most likely to produce a rapid reversal.